Celldex Therapeutics, Inc. Share Price London S.E.
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 2.77B 2.43B 2.26B 2.08B 3.9B 267B 3.96B 26.86B 10.49B 131B 10.4B 10.17B 453B | P/E 2026 * |
-8.13x | P/E 2027 * | -8.13x |
|---|---|---|---|---|---|
| Enterprise Value | 2.19B 1.92B 1.78B 1.64B 3.08B 210B 3.12B 21.19B 8.28B 103B 8.2B 8.03B 358B | EV / Sales 2026 * |
904x | EV / Sales 2027 * | 204x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | -2.26% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 29/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 31/08/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 31/03/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 30/11/2008 |
Harry Penner
CHM | Chairman | 80 | 04/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 29/02/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.26% | -.--% | - | - | 2.77B | |
| +1.07% | -3.49% | -3.35% | +11.75% | 46.86B | |
| +0.25% | +1.65% | +399.22% | +647.65% | 40.23B | |
| -0.27% | +4.45% | +11.81% | +60.81% | 36.23B | |
| +0.35% | +0.87% | +4.46% | -10.31% | 34.72B | |
| +3.14% | +1.02% | +4.76% | +43.00% | 27.89B | |
| -0.73% | +11.84% | +34.39% | +134.44% | 16.79B | |
| +0.47% | -2.74% | - | - | 16.74B | |
| +0.42% | -5.52% | -3.43% | +9.10% | 13.12B | |
| -2.68% | -2.49% | -11.36% | -34.51% | 12.7B | |
| Average | -0.02% | +0.83% | +54.56% | +107.74% | 27.25B | |
| Weighted average by Cap. | +0.45% | +0.91% | +74.42% | +138.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.42M 2.12M 1.97M 1.81M 3.4M 233M 3.46M 23.44M 9.16M 114M 9.07M 8.88M 396M | 11.04M 9.7M 9.02M 8.28M 15.55M 1.06B 15.79M 107M 41.84M 523M 41.45M 40.56M 1.81B |
| Net income | -330M -290M -270M -247M -465M -31.79B -472M -3.2B -1.25B -15.63B -1.24B -1.21B -54.03B | -367M -323M -300M -275M -518M -35.39B -526M -3.56B -1.39B -17.4B -1.38B -1.35B -60.16B |
| Net Debt | -584M -513M -477M -438M -823M -56.25B -835M -5.67B -2.21B -27.65B -2.19B -2.15B -95.62B | -515M -452M -421M -386M -725M -49.6B -737M -5B -1.95B -24.39B -1.93B -1.89B -84.32B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
